ANN ARBOR, MI / ACCESSWIRE / August 4, 2023 / Zomedica Corp. (NYSE American:ZOM) ("Zomedica" or the "Company"), a veterinary health company offering diagnostic and therapeutic products for companion animals, will host a conference call and audio-only webcast on Thursday, August 10, 2023 at 4:30 p.m. ET to discuss the Company's operational and financial highlights for its second quarter ending June 30, 2023. A question-and-answer session will follow management's prepared remarks.
Event: Zomedica Q2 2023 Financial Result Conference Call
Date: Thursday, August 10, 2023
Time: 4:30 p.m. Eastern Time
Live Call: +1-888-886-7786 (U.S. Toll-Free) or +1-416-764-8658 (International)
Webcast: https://viavid.webcasts.com/starthere.jsp?ei=1625619&tp_key=8db2f382d8
For interested individuals unable to join the conference call, a dial-in replay of the call will be available until August 24, 2023 at 11:59 p.m. ET and can be accessed by dialing +1-844-512-2921 (U.S. Toll-Free) or +1-412-317-6671 (International) and entering replay pin number: 77164792.
About Zomedica
Based in Ann Arbor, Michigan, Zomedica (NYSE American: ZOM) is a veterinary health company creating products for companion animals by focusing on the unmet needs of clinical veterinarians. Zomedica's product portfolio will include innovative diagnostics and medical devices that emphasize patient health and practice health. It is Zomedica's mission to provide veterinarians the opportunity to increase productivity and grow revenue while better serving the animals in their care. For more information, visit www.ZOMEDICA.com.
Follow Zomedica
Email Alerts: http://investors.zomedica.com
LinkedIn: https://www.linkedin.com/company/zomedica
Facebook: https://m.facebook.com/zomedica
Twitter: https://twitter.com/zomedica
Instagram: https://www.instagram.com/zomedica_inc
Investor Relations Contact:
RedChip Companies Inc.
Barrett Boone
This email address is being protected from spambots. You need JavaScript enabled to view it.
407-571-0912
Last Trade: | US$0.04 |
Daily Volume: | 735,048 |
May 13, 2025 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load